Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2024-09-30 DOI:10.1080/14796694.2024.2402639

Lisa B Leypoldt, Diana Tichy, Britta Besemer, Mathias Hanel, Marc S Raab, Christoph Mann, Markus Munder, Hans Christian Reinhardt, Axel Nogai, Martin Gorner, Yon-Dschun Ko, Maike de Wit, Hans Salwender, Christof Scheid, Ullrich Graeven, Rudolf Peceny, Peter Staib, Annette Dieing, Hermann Einsele, Anna Jauch, Michael Hundemer, Manola Zago, Ema Pozek, Axel Benner, Carsten Bokemeyer, Hartmut Goldschmidt, Katja C Weisel

引用次数: 0

查看原文本刊更多论文

关于伊沙妥昔单抗联合卡非佐米、来那度胺和地塞米松治疗高风险新诊断多发性骨髓瘤患者的纯文字摘要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.